These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 29211615)
21. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Carel JC; Eugster EA; Rogol A; Ghizzoni L; Palmert MR; ; Antoniazzi F; Berenbaum S; Bourguignon JP; Chrousos GP; Coste J; Deal S; de Vries L; Foster C; Heger S; Holland J; Jahnukainen K; Juul A; Kaplowitz P; Lahlou N; Lee MM; Lee P; Merke DP; Neely EK; Oostdijk W; Phillip M; Rosenfield RL; Shulman D; Styne D; Tauber M; Wit JM Pediatrics; 2009 Apr; 123(4):e752-62. PubMed ID: 19332438 [TBL] [Abstract][Full Text] [Related]
22. A clinician's guide to the use of gonadotropin-releasing hormone analogues in women. Moghissi KS Medscape Womens Health; 2000 Jan; 5(1):5. PubMed ID: 10792849 [TBL] [Abstract][Full Text] [Related]
23. Precocious puberty and statural growth. Carel JC; Lahlou N; Roger M; Chaussain JL Hum Reprod Update; 2004; 10(2):135-47. PubMed ID: 15073143 [TBL] [Abstract][Full Text] [Related]
24. The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK. Rosario DJ; Davey P; Green J; Greene D; Turner B; Payne H; Kirby M World J Urol; 2016 Dec; 34(12):1601-1609. PubMed ID: 27097892 [TBL] [Abstract][Full Text] [Related]
25. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate). Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897 [TBL] [Abstract][Full Text] [Related]
26. Gonadotropin-releasing hormone and its clinical applications. Loucopoulos A; Ferin M Obstet Gynecol Annu; 1984; 13():275-88. PubMed ID: 6326010 [TBL] [Abstract][Full Text] [Related]
27. Insight: prolonged vaginal bleeding during central precocious puberty therapy with a long-acting gonadotropin-releasing hormone agonist: a proposed mechanism and management plan. Kauschansky A; Orvieto R; Yeshaya A; Shterntal B; Naor Z J Pediatr Adolesc Gynecol; 2011 Dec; 24(6):365-7. PubMed ID: 21872518 [TBL] [Abstract][Full Text] [Related]
28. Subcutaneous gonadotropin-releasing hormone agonist (triptorelin) test for diagnosing precocious puberty. Poomthavorn P; Khlairit P; Mahachoklertwattana P Horm Res; 2009; 72(2):114-9. PubMed ID: 19690429 [TBL] [Abstract][Full Text] [Related]
29. Management of short stature with GnRH agonist and co-treatment with growth hormone: a controversial issue. Carel JC Mol Cell Endocrinol; 2006 Jul; 254-255():226-33. PubMed ID: 16787697 [TBL] [Abstract][Full Text] [Related]
30. The effects of gonadotropin releasing hormone analogue therapy on girls with gonadotropin-dependent precocious puberty. Tung YC; Lee JS; Tsai WY; Hsiao PH J Formos Med Assoc; 2007 Oct; 106(10):826-31. PubMed ID: 17964961 [TBL] [Abstract][Full Text] [Related]
32. Investigational and experimental GnRH analogs and associated neurotransmitters. Blumenfeld Z Expert Opin Investig Drugs; 2017 Jun; 26(6):661-667. PubMed ID: 28441891 [TBL] [Abstract][Full Text] [Related]
33. Treatment of central precocious puberty: comparison of urinary gonadotropin excretion and gonadotropin-releasing hormone (GnRH) stimulation tests in monitoring GnRH analog therapy. Witchel SF; Baens-Bailon RG; Lee PA J Clin Endocrinol Metab; 1996 Apr; 81(4):1353-6. PubMed ID: 8636332 [TBL] [Abstract][Full Text] [Related]
34. Use of GnRH agonists in GH-deficient patients: arguments for and against. The case for GnRH agonists in GH-deficient patients. Lee PA Pediatr Endocrinol Rev; 2008 Feb; 5 Suppl 2():744-9. PubMed ID: 18317446 [TBL] [Abstract][Full Text] [Related]
35. [Effect of treatment with gonadotropin releasing hormone analogues in girls with idiopathic central precocious puberty]. Ságodi L; Sólyom E; Lombay B; Almási A; Vámosi I Orv Hetil; 2012 Mar; 153(11):418-24. PubMed ID: 22390866 [TBL] [Abstract][Full Text] [Related]
36. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. Smith MR; Lee WC; Brandman J; Wang Q; Botteman M; Pashos CL J Clin Oncol; 2005 Nov; 23(31):7897-903. PubMed ID: 16258089 [TBL] [Abstract][Full Text] [Related]
37. Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis. Hosseini SA; Rajabi F; Akbari Sari A; Ayati M; Heidari S; Ghamary F Med J Islam Repub Iran; 2016; 30():317. PubMed ID: 27390687 [TBL] [Abstract][Full Text] [Related]
38. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists]. Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586 [TBL] [Abstract][Full Text] [Related]
39. Gonadotropin-releasing hormone antagonist: A real advantage? Kimura T; Sasaki H; Akazawa K; Egawa S Urol Oncol; 2015 Jul; 33(7):322-8. PubMed ID: 26070474 [TBL] [Abstract][Full Text] [Related]